Compare Alphabet Inc Class A (GOOGL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs ResMed Inc. — how do they compare? Alphabet Inc Class A trades at $371.38 (market cap $4.52T), while ResMed Inc. trades at $201.68 (market cap $28.80B). The key difference: Alphabet Inc Class A is far larger — about 156.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| GOOGL | RMD | |
|---|---|---|
Market Cap | $4.52T | $28.80B |
Sector | Media | Health |
52-Week High | $402.62 | $293.73 |
52-Week Low | $182.97 | $182.82 |
Enterprise Value | $4.49T | $27.99B |
Dividend Yield | 0.24% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) stock trades at $370.92, up 3.17% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $350B in 2024 to $402.8B in 2025 and net income surging 32% to $132.2B. Recent quarterly earnings consistently beat expectations, and the company initiated a dividend in 2026. Analyst sentiment remains overwhelmingly positive with 85% buy ratings and a $431.78 consensus price target, suggesting 16% upside potential.
The outlook for GOOGL appears favorable given strong AI-driven growth in cloud and advertising, expanding profitability margins, and solid cash flow generation. Key risks include regulatory scrutiny of antitrust practices, competitive pressures in AI and cloud services, and potential market volatility affecting tech valuations. The stock's current valuation at 28.29x P/E reflects premium pricing for its growth trajectory.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
